Abstract: A liquid crystal display (LCD) of the chiral polymer stabilized alignment (C-PSA) mode, a method of its production and its use as an energy-saving display.

Abstract: The present invention relates to methods for purifying adeno-associated virus particles by cation exchange mixed mode chromatography.

Abstract: Compounds of Formula 1 and pharmaceutically acceptable compositions thereof are useful as TLR7/8 antagonists.

Abstract: A liquid-crystal (LC) medium containing one or more dyes and one or more polymerizable compounds, its use for optical, electro-optical and electronic purposes, in particular in LC displays, especially in colour LC displays of the PSA (polymer sustained alignment) or SA (self-aligning) mode containing a quantum dot colour filter (QDCF), an LC display of the PSA or SA mode containing the LC medium and containing a QDCF, and to a process of manufacturing the LC display.

Abstract: The present invention relates to combination therapies useful for the treatment of cancer. In particular, the invention relates to a therapeutic combination which comprises a PD-1 antagonist, an ATR inhibitor and a platinating agent.

Abstract: The present invention relates to novel 5-azaindazole derivatives of formula (I), as described and defined herein, and pharmaceutically acceptable salts, solvates and prodrug thereof, as well as pharmaceutical compositions comprising such compounds. The 5-azaindazole derivatives according to the invention have been found to be highly effective dual A2A/A2B adenosine receptor antagonists, and can thus be used as therapeutic agents, particularly in the treatment or prevention of hyperproliferative or infectious diseases or disorders.

Abstract: A silicon precursor compound according to Formula I as described herein is used to form a silicon-containing thin film having excellent quality. A preparation method therefor, and a silicon-containing thin film preparation method using the silicon precursor compound are also described.

Abstract: A semiconducting light emitting nanoparticle is described having a core and shell structure. The particle has a core and an outer layer or shell. The outer layer covers at least part of the core and contains a metal cation and a divalent anion. Additionally, one or more organic moieties are directly attached to the anion of the outer layer by covalent bond. The divalent anion is Se2?, S2?, Te2?, O2? or a combination thereof. The metal cation can be a monovalent, cation, trivalent, or tetravalent cation. Also, a process for synthesizing the semiconducting light emitting nanoparticle is described.

Abstract: The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid and an amino acid ethyl ester like L-phenylalanine ethyl ester or L-methionine ethyl ester, wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to amino acid ethyl ester is from 1:0.3 to 1:3.0 (in mol/mol) and/or hydrates and/or solvates thereof as well as to a process of obtaining the same.

Abstract: Method and system to analyze biomasses in a bioreactor (3) via a computer (2) with a system software (5), the bioreactor (3) having at least one sensor (6) to measure the biomasses and which has a data connection to the computer (2) managed by a data interface provided by the system software (5), wherein the system software (5) provides a data conversion model (8) to analyze real time raw data about permittivity measured by and transmitted from the at least one sensor (6) to the computer (2) to calculate specific cell parameters of cells in the biomasses.

Abstract: The new media exhibit a ferroelectric nematic phase preferably at ambient temperature. They preferably comprise one or more compounds selected from the group of compounds of formulae IA, IB and IC, in which the variable groups have the meanings indicated in the text and in the claims. Use of the media for providing ferroelectric nematic materials and a method of operation of an electro-optical device are presented. The media may be useful for energy-saving displays and electrical appliances.

Abstract: The present application concerns compounds for use in electronic devices, processes for preparing the compounds, and electronic devices comprising the compounds.

Abstract: The present invention relates to immunoglobulins that bind ADAMTS5 and more in particular to polypeptides, that comprise or essentially consist of one or more such immunoglobulins. The invention also relates to constructs comprising such immunoglobulins, such as immunoglobulin single variable domains (ISVDs) or polypeptides as well as nucleic acids encoding such immunoglobulins or polypeptides; to methods for preparing such immunoglobulins, polypeptides and constructs; to host cells expressing or capable of expressing such immunoglobulins or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such immunoglobulins, polypeptides, constructs, nucleic acids and/or host cells; and to uses of immunoglobulins, polypeptides, constructs, nucleic acids, host cells and/or compositions, in particular for prophylactic and/or therapeutic purposes, such as the prophylactic and/or therapeutic purposes mentioned herein.

Abstract: The invention relates to liquid-crystalline media which can be used, in particular, for electro-optical displays having active-matrix addressing based on the ECB effect and for IPS (in-plane switching) displays or FFS (fringe field switching) displays.

Abstract: The present invention relates to a compound of formula GF in which the occurring groups and parameters have the meanings defined in claim 1, to a liquid crystal medium comprising a compound of formula GF and to high-frequency components comprising these media, especially microwave components for high-frequency devices, such as devices for shifting the phase of microwaves, tunable filters, tunable metamaterial structures, and electronic beam steering antennas, e.g. phased array antennas.

Abstract: The present invention provides compounds of Formula I?, or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for treating cellular proliferative disorders (e.g., cancer).

Abstract: According to the organometallic compound of the present invention and the thin film manufactured using the same, requirements of high volatility and excellent chemical/thermal stability are satisfied, and significantly improved thin-film deposition rates are exhibited even at low temperatures. In addition, property degradation due to by-products can be improved, excellent step coverage can be realized, and a thin film which, due to having a high dielectric constant, electrically satisfies the equivalent oxide thickness (EOT) requirement while having a thickness at which tunneling does not physically occur can be implemented.

Abstract: The present invention relates to novel 5-azaindazole derivatives of formula (I), as described and defined herein, and pharmaceutically acceptable salts, solvates and prodrug thereof, as well as pharmaceutical compositions comprising such compounds. The 5-azaindazole derivatives according to the invention have been found to be highly effective dual A2A/A2B adenosine receptor antagonists, and can thus be used as therapeutic agents, particularly in the treatment or prevention of hyperproliferative or infectious diseases or disorders.

Abstract: A liquid-crystal (LC) medium which is based on a mixture of polar compounds and is substantially dielectrically neutral, its use for optical, electro-optical and electronic purposes, in particular as optical retarder or optical compensator in LC displays, an optical retarder or optical compensator containing the LC medium, an optical, electrooptical or electronic device containing the optical retarder or optical compensator, and a process of manufacturing the optical retarder or optical compensator.